Dusa Pharma (Dusa)

[surf1944]

DUSA Announces Patent Licensing Agreement
Thursday August 14, 6:30 am ET

WILMINGTON, MASSACHUSETTS--(MARKET WIRE)--Aug 14, 2008 -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license. As part of the agreement, DUSA will receive a share of the net revenues River's Edge generates.

"DUSA is pleased to have reached this new patent license agreement," said Bob Doman, President and CEO of DUSA. "We believe that this agreement and other commercial strategies will allow DUSA to maximize the value of this asset."

In October 2007, DUSA and River's Edge signed a settlement and mutual release to settle patent litigation, which is being amended to accommodate this new patent license agreement.